

# Richard Haynes

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2959438/richard-haynes-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

89  
papers

11,446  
citations

30  
h-index

99  
g-index

99  
ext. papers

15,989  
ext. citations

13.5  
avg, IF

6.5  
L-index

#	Paper	IF	Citations
89	Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials. <i>EClinicalMedicine</i> , <b>2021</b> , 41, 101163	11.3	1
88	Tocilizumab in COVID-19 therapy: who benefits, and how? - AuthorsTreply. <i>Lancet, The</i> , <b>2021</b> , 398, 300	40	1
87	Cardiac, renal, and metabolic effects of sodium-glucose co-transporter 2 inhibitors: a position paper from the European Society of Cardiology ad-hoc task force on sodium-glucose co-transporter 2 inhibitors. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 1260-1275	12.3	12
86	Dexamethasone in Hospitalized Patients with Covid-19. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 693-704	59.2	4434
85	TaleNepriylsin and Nepriylsin inhibition in chronic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , <b>2021</b> , 30, 123-130	3.5	6
84	Conventional and Genetic Evidence on the Association between Adiposity and CKD. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2021</b> , 32, 127-137	12.7	9
83	Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , <b>2021</b> , 326, 499-518	27.4	154
82	Comparison of the Accuracy and Completeness of Records of Serious Vascular Events in Routinely Collected Data vs Clinical Trial-Adjudicated Direct Follow-up Data in the UK: Secondary Analysis of the ASCEND Randomized Clinical Trial.. <i>JAMA Network Open</i> , <b>2021</b> , 4, e2139748	10.4	5
81	Effects of Omega-3 Fatty Acid Supplements on Arrhythmias. <i>Circulation</i> , <b>2020</b> , 141, 331-333	16.7	9
80	Kidney disease trials for the 21st century: innovations in design and conduct. <i>Nature Reviews Nephrology</i> , <b>2020</b> , 16, 173-185	14.9	8
79	Apolipoprotein B, Triglyceride-Rich Lipoproteins, and Risk of Cardiovascular Events in Persons with CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2020</b> , 15, 47-60	6.9	18
78	Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. <i>New England Journal of Medicine</i> , <b>2020</b> , 383, 2030-2040	59.2	628
77	Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. <i>Lancet, The</i> , <b>2020</b> , 396, 1345-1352	40	340
76	International consensus definitions of clinical trial outcomes for kidney failure: 2020. <i>Kidney International</i> , <b>2020</b> , 98, 849-859	9.9	19
75	Cross-sectional associations between central and general adiposity with albuminuria: observations from 400,000 people in UK Biobank. <i>International Journal of Obesity</i> , <b>2020</b> , 44, 2256-2266	5.5	3
74	Independent risk factors for simvastatin-related myopathy and relevance to different types of muscle symptom. <i>European Heart Journal</i> , <b>2020</b> , 41, 3336-3342	9.5	17
73	Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , <b>2020</b> , 324, 1330-1341	27.4	1083

72	Chronic kidney disease, heart failure and neprilysin inhibition. <i>Nephrology Dialysis Transplantation</i> , <b>2020</b> , 35, 558-564	4.3	19
71	Serious Adverse Effects of Extended-release Niacin/Laropiprant: Results From the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) Trial. <i>Clinical Therapeutics</i> , <b>2019</b> , 41, 1767-1777	3.5	11
70	Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease. <i>Kidney International</i> , <b>2019</b> , 96, 170-179	9.9	5
69	Assessment of Vascular Event Prevention and Cognitive Function Among Older Adults With Preexisting Vascular Disease or Diabetes: A Secondary Analysis of 3 Randomized Clinical Trials. <i>JAMA Network Open</i> , <b>2019</b> , 2, e190223	10.4	9
68	Investigating modifications to participant information materials to improve recruitment into a large randomized trial. <i>Trials</i> , <b>2019</b> , 20, 681	2.8	1
67	Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection. <i>Nephrology Dialysis Transplantation</i> , <b>2018</b> , 33, 257-264	4.3	6
66	Declining comorbidity-adjusted mortality rates in English patients receiving maintenance renal replacement therapy. <i>Kidney International</i> , <b>2018</b> , 93, 1165-1174	9.9	16
65	The role of lipoprotein (a) in chronic kidney disease. <i>Journal of Lipid Research</i> , <b>2018</b> , 59, 577-585	6.3	37
64	ASCEND: A Study of Cardiovascular Events in Diabetes: Characteristics of a randomized trial of aspirin and of omega-3 fatty acid supplementation in 15,480 people with diabetes. <i>American Heart Journal</i> , <b>2018</b> , 198, 135-144	4.9	48
63	Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease. <i>Circulation</i> , <b>2018</b> , 138, 1505-1514	16.7	79
62	Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. <i>New England Journal of Medicine</i> , <b>2018</b> , 379, 1529-1539	59.2	532
61	Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus. <i>New England Journal of Medicine</i> , <b>2018</b> , 379, 1540-1550	59.2	338
60	Feasibility of Telemonitoring Blood Pressure in Patients With Kidney Disease (Oxford Heart and Renal Protection Study-1): Observational Study. <i>JMIR Cardio</i> , <b>2018</b> , 2,	3.1	2
59	Campath, calcineurin inhibitor reduction, and chronic allograft nephropathy (the 3C Study) - results of a randomized controlled clinical trial. <i>American Journal of Transplantation</i> , <b>2018</b> , 18, 1424-1434	8.7	13
58	Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation. <i>Kidney International</i> , <b>2018</b> , 93, 1000-1007	9.9	21
57	The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study. <i>CKJ: Clinical Kidney Journal</i> , <b>2018</b> , 11, 749-761	4.5	120
56	Impact of Apolipoprotein(a) Isoform Size on Lipoprotein(a) Lowering in the HPS2-THRIVE Study. <i>Circulation Genomic and Precision Medicine</i> , <b>2018</b> , 11, e001696	5.2	38
55	PCSK9 inhibition: ready for prime time in CKD?. <i>Kidney International</i> , <b>2018</b> , 93, 1267-1269	9.9	7

54	Fibroblast Growth Factor-23 and Risks of Cardiovascular and Noncardiovascular Diseases: A Meta-Analysis. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2018</b> , 29, 2015-2027	12.7	100
53	Biliary Tract and Liver Complications in Polycystic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2017</b> , 28, 2738-2748	12.7	14
52	Evidence for Reverse Causality in the Association Between Blood Pressure and Cardiovascular Risk in Patients With Chronic Kidney Disease. <i>Hypertension</i> , <b>2017</b> , 69, 314-322	8.5	19
51	Use of Causal Diagrams to Inform the Design and Interpretation of Observational Studies: An Example from the Study of Heart and Renal Protection (SHARP). <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2017</b> , 12, 546-552	6.9	24
50	A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease. <i>Heart</i> , <b>2017</b> , 103, 1880-1890	5.1	16
49	Effects of Vascular and Nonvascular Adverse Events and of Extended-Release Niacin With Laropiprant on Health and Healthcare Costs. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2016</b> , 9, 348-54	5.8	3
48	Outcomes of Elderly Patients with Anti-Neutrophil Cytoplasmic Autoantibody-Associated Vasculitis Treated with Immunosuppressive Therapy. <i>Nephron</i> , <b>2016</b> , 133, 223-31	3.3	0
47	Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP). <i>American Journal of Kidney Diseases</i> , <b>2016</b> , 68, 371-80	7.4	37
46	The Safety and Efficacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta-analysis. <i>American Journal of Kidney Diseases</i> , <b>2016</b> , 68, 591-598	7.4	55
45	Impact of Educational Attainment on Health Outcomes in Moderate to Severe CKD. <i>American Journal of Kidney Diseases</i> , <b>2016</b> , 67, 31-9	7.4	26
44	Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP). <i>American Journal of Kidney Diseases</i> , <b>2016</b> , 67, 576-84	7.4	16
43	Cost-effective recruitment methods for a large randomised trial in people with diabetes: A Study of Cardiovascular Events in Diabetes (ASCEND). <i>Trials</i> , <b>2016</b> , 17, 286	2.8	26
42	Effect of Processing Delay and Storage Conditions on Urine Albumin-to-Creatinine Ratio. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2016</b> , 11, 1794-1801	6.9	12
41	Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. <i>Lancet Diabetes and Endocrinology</i> , <b>2016</b> , 4, 829-39	18.1	158
40	Chronic kidney disease: Statins in chronic kidney disease: time to move on?. <i>Nature Reviews Nephrology</i> , <b>2015</b> , 11, 262-3	14.9	4
39	Neprilysin inhibition in chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , <b>2015</b> , 30, 738-43	4.3	63
38	Alemtuzumab induction therapy in kidney transplantation - AuthorsTreply. <i>Lancet, The</i> , <b>2015</b> , 385, 771	4.0	
37	Use of gel-based separator tubes to stabilise phosphate in mailed blood samples. <i>Clinica Chimica Acta</i> , <b>2015</b> , 439, 112-4	6.2	

36	Evidence for the prevention and treatment of stroke in dialysis patients. <i>Seminars in Dialysis</i> , <b>2015</b> , 28, 35-47	2.5	35
35	What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?. <i>BMC Nephrology</i> , <b>2015</b> , 16, 65	2.7	53
34	Evaluating the contribution of the cause of kidney disease to prognosis in CKD: results from the Study of Heart and Renal Protection (SHARP). <i>American Journal of Kidney Diseases</i> , <b>2014</b> , 64, 40-8	7.4	46
33	Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial. <i>Lancet, The</i> , <b>2014</b> , 384, 1684-90	40	105
32	Effects of extended-release niacin with laropiprant in high-risk patients. <i>New England Journal of Medicine</i> , <b>2014</b> , 371, 203-12	59.2	1073
31	The effect of lowering LDL cholesterol on vascular access patency: post hoc analysis of the Study of Heart and Renal Protection. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2014</b> , 9, 914-9	6.9	12
30	Niacin for reduction of cardiovascular risk. <i>New England Journal of Medicine</i> , <b>2014</b> , 371, 1943-4	59.2	6
29	Effects of lowering LDL cholesterol on progression of kidney disease. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2014</b> , 25, 1825-33	12.7	108
28	Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (3C) study: background, rationale, and study protocol. <i>Transplantation Research</i> , <b>2013</b> , 2, 7		20
27	Quiz page September 2013: a crystal clear diagnosis. <i>American Journal of Kidney Diseases</i> , <b>2013</b> , 62, xxvi-xxix		2
26	Chronic kidney disease: Does serum phosphate predict death and ESRD in CKD patients?. <i>Nature Reviews Nephrology</i> , <b>2013</b> , 9, 438-9	14.9	3
25	Myeloma kidney: improving clinical outcomes?. <i>Advances in Chronic Kidney Disease</i> , <b>2012</b> , 19, 342-51	4.7	9
24	Management of Long-Term Complications <b>2012</b> , 403-436		
23	Survival after starting renal replacement treatment in patients with autosomal dominant polycystic kidney disease: a single-centre 40-year study. <i>Nephron Clinical Practice</i> , <b>2012</b> , 120, c42-7		11
22	Cardiovascular Aspects of Kidney Disease <b>2012</b> , 2059-2080		5
21	Alemtuzumab: right drug, right dose?. <i>Transplant International</i> , <b>2011</b> , 24, 1051-2	3	2
20	Clinical trials of lipid-modifying agents: design considerations. <i>Clinical Lipidology</i> , <b>2011</b> , 6, 109-116		
19	Serum free light chains and the risk of ESRD and death in CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2011</b> , 6, 2829-37	6.9	25

18	Late presentation of patients with end-stage renal disease for renal replacement therapy--is it always avoidable?. <i>Nephrology Dialysis Transplantation</i> , <b>2011</b> , 26, 3646-51	4.3	18
17	Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2010</b> , 303, 2486-94	27.4	235
16	How the NHS research governance procedures could be modified to greatly strengthen clinical research. <i>Clinical Medicine</i> , <b>2010</b> , 10, 127-9	1.9	5
15	Screening for risk with albuminuria: should we start from here?. <i>Nephrology Dialysis Transplantation</i> , <b>2010</b> , 25, 3463-5	4.3	1
14	Lipids in chronic kidney disease. <i>Journal of Renal Care</i> , <b>2010</b> , 36 Suppl 1, 27-33	1.6	11
13	Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. <i>Lancet, The</i> , <b>2010</b> , 376, 1658-69	40	416
12	Reassuring results with regard to the effect of donor nephrectomy on cardiovascular outcomes. <i>Nature Reviews Nephrology</i> , <b>2009</b> , 5, 126-7	14.9	1
11	Aspirin for primary prevention of vascular disease in people with diabetes. <i>BMJ, The</i> , <b>2009</b> , 339, b4596	5.9	3
10	Fluvastatin for reduction of cardiovascular risk in patients with moderate to severe renal insufficiency. <i>Nature Clinical Practice Nephrology</i> , <b>2007</b> , 3, 530-1		
9	Proteinuria. <i>BMJ, The</i> , <b>2006</b> , 332, 284	5.9	6
8	Effect of Dexamethasone in Hospitalized Patients with COVID-19 [Preliminary Report]		313
7	Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial		82
6	Azithromycin in Hospitalised Patients with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial		4
5	Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial		11
4	Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial		11
3	Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial		5
2	Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial		37
1	Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial		65

